Table 3.
Next-Generation Type I Jak2-inhibitors with terminated clinical development.
| Drug Name | Mechanism | Indication | NCT # | Trial Phase | Outcome |
|---|---|---|---|---|---|
| AZD1480 | Jak1/2 inhibitor (Type I) [110] | Primary myelofibrosis and post-PCV/ET-MF | NCT 00910728 | 1 | Terminated (toxicity) |
| Solid tumors, gastric cancer, HCC, NSCLC | NCT 01219543 | 1 | Terminated (toxicity) | ||
| Solid tumors | NCT 01112397 | 1 | Terminated (toxicity) | ||
| XL019 | Jak2 inhibitor (Type 1) | PCV | NCT 00595829 | 1 | Terminated (toxicity) |
| MF | NCT 00522574 | 1 | Terminated (toxicity) | ||
| BMS-911543 | Jak2 inhibitor | MF | NCT 01236352 | 1/2 | Terminated (business decision) |
| MK-0457/VX680 | Aurora kinase inhibitor | NCT 00111683 | 1 | Terminated (toxicity) | |
| NCT 02532868 | 1 | Terminated (toxicity) | |||
| NCT 00290550 | 2a | Terminated (toxicity) | |||
| NCT 00405054 | 2 | Terminated (toxicity) | |||
| NCT 00099346 | 1 | Terminated (toxicity) | |||
| NCT 00500006 | 1 | Terminated (toxicity) |
Information in this chart has been sourced from ClinicalTrials.gov. Abbreviations: HCC: Hepatocellular carcinoma, NSCLC: Non-small Cell Lung Carcinoma, MF: Myelofibrosis, PCV: Polycythemia Vera, ET: Essential Thrombocythemia.